BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 12, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

The U.K.'s NICE issued an preliminary appraisal recommending against the use of Avastin bevacizumab from Roche in combination with a taxane for the first-line treatment of metastatic breast cancer. Comments are due by July 30.

NICE estimated the incremental cost-effectiveness ratio (ICER) for Avastin plus paclitaxel vs. weekly paclitaxel...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >